Dunhill Financial’s Acadia Pharmaceuticals ACAD Stock Holding History

Dunhill Financial’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2	Closed	-$48	–	1620
2026 Q1	$48	Hold	2	–	–	﹤0.01%	1616
2025 Q4	$58	Buy	+2	New	+$48	﹤0.01%	1598

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Dunhill Financial's ACAD Position: Q2 2026 in Review

Dunhill Financial sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 2 shares — an estimated $48 sold.

Dunhill Financial first reported a position in ACAD in Q4 2025 and held it in 2 quarters. The position peaked at $58 in Q4 2025. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Dunhill Financial reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Dunhill Financial sold 2 Acadia Pharmaceuticals shares in Q2 2026, an estimated $48.
Dunhill Financial first reported a position in Acadia Pharmaceuticals in Q4 2025 and held it in 2 quarters.
Dunhill Financial's Acadia Pharmaceuticals position peaked at $58 in Q4 2025.
353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.